News | Intravascular Imaging | August 10, 2018

Infraredx Announces Japanese Launch of Makoto Intravascular Imaging System and Dualpro IVUS+NIRS Catheter

Dual-modality intravascular imaging system saw limited market release in spring 2018

 

Infraredx Announces Japanese Launch of Makoto Intravascular Imaging System and Dualpro IVUS+NIRS Catheter

August 10, 2018 — Infraredx Inc. announced the Makoto Intravascular Imaging System, and accompanying Dualpro intravascular ultrasound and near-infrared spectroscopy (IVUS+NIRS) catheter, is now available in Japan. The launch follows a successful Spring 2018 limited market release, which included more than 10 hospitals in Japan.

The Makoto Intravascular Imaging System and Dualpro catheter is the only technology on the market, according to Infraredx, to identify vessel structure and plaque composition using IVUS+NIRS. Its launch follows market approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) in August 2017.

“In Japan, we rely heavily on intravascular imaging during percutaneous coronary intervention; so much so that is has become the standard of care, with approximately 90 percent of angioplasty procedures employing intravascular imaging,” said Takashi Kubo, M.D., Ph.D.., Wakayama Medical University. “The Makoto Imaging System and Dualpro catheter is the next generation of imaging technology, providing superior deliverability and lesion crossing ability as well as best-in-class image resolution to easily identify the degree of stenosis and plaque burden.”

According to Infraredx, Dualpro is the only imaging catheter on the market equipped with extended bandwidth IVUS technology. By emitting and processing a broad band of frequencies, the Dualpro IVUS provides high image resolution without compromising depth of field. Data collected from the NIRS technology are translated into a Chemogram, an easy-to-interpret, color-coded map to identify lipid core plaque (LCP), which can help distinguish between stable plaque and dangerous LCP.

There are several global landmark studies, including the Lipid-Rich Plaque (LRP) Study, currently underway, which underscore the importance of identifying LCP for the prediction, and ultimately prevention, of serious heart attacks. Results of the prospective, multi-center LRP Study, along with a U.S. market launch of the Makoto Imaging System and Dualpro IVUS+NIRS catheter, are anticipated in the second half 2018. The technology is currently the only U.S. Food and Drug Administration (FDA)-cleared dual-modality catheter and imaging system indicated for the detection of LCP.

For more information: www.infraredx.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major